Skip to main content
. 2022 Dec 30;17(3):606–614. doi: 10.1007/s12072-022-10453-1

Fig. 4.

Fig. 4

Pre- and post-laboratory data of pemafibrate treatment for 48 weeks. Liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), and FibroScan-aspartate aminotransferase (FAST) score were shown. Data are expressed as mean with standard error of the mean (SEM). *p < 0.05